Peter Nash

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

P. Mease, S. Jugl, S. Mpofu, 2018 .

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

R. Landewé, V. Bykerk, J. Gottenberg, 2017 .

The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

U. Müller-Ladner, L. Czirják, C. Denton, 2009, Annals of the rheumatic diseases.

Seronegative spondyloarthropathies: to lump or split?

D. M. van der Heijde, P. Mease, J. Braun, 2005, Annals of the rheumatic diseases.

OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)

M. Genovese, P. Rahman, B. Kirkham, 2017 .